NCT04408599View on ClinicalTrials.gov

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 10, 2020

Primary Completion Date

July 6, 2023

Study Completion Date

July 6, 2023

Conditions
Advanced or Metastatic Solid TumorsOvarian CancerGastric CancerColo-rectal Cancer
Interventions
DRUG

NC410

NC410 is an experimental antibody drug that may make the immune response more active against cancer

Trial Locations (5)

10016

NYU Langone Health, New York

15232

UPMC Hillman Cancer Center, Pittsburgh

20892

NIH National Cancer Institute (NCI), Bethesda

77030

UT MD Anderson Cancer Center, Houston

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

NextCure, Inc.
All Listed Sponsors
lead

NextCure, Inc.

INDUSTRY

NCT04408599 - A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter